Alkermes plc.

in this Annual Report for information with respect to the IP protection for these marketed products. 7 The following provides summary information regarding our proprietary products that we commercialize: Proprietary Products Product Indicated Disease State Territory Initiation or re-initiation of ARISTADA for the treatment of Schizophrenia U.S. Schizophrenia U.S. Narcolepsy U.S. Schizophrenia; Bipolar I disorder U.S. Alcohol dependence; Opioid dependence U.S. 8 The following provides summary information regarding certain key third-party products using our proprietary technologies under license and our key licensed product, that are commercialized by our licensees: Key Third-Party Products Using Our Proprietary Technologies Product Indicated Disease State Licensee Licensed Territory RISPERDAL CONSTA Schizophrenia; Bipolar I disorder Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica International, a division of Cilag International AG ( Janssen International ) Worldwide INVEGA SUSTENNA / XEPLION INVEGA SUSTENNA : Schizophrenia; Schizoaffective disorder XEPLION : Schizophrenia Janssen Pharmaceutica N.V.